Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(29 sites)

China

Anhui Provincial Hospital, Hefei, Anhui

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing Municipality

Beijing Cancer Hospital, Beijing, Beijing Municipality

Chongqing Cancer Hospital, Chongqing, Chongqing Municipality

Fujian Medical University Union Hospital, Fuzhou, Fujian

Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong

Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong

The Sixth Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong

Huizhou First Hospital, Huizhou, Guangdong

Meizhou People Hospital, Meizhou, Guangdong

The Peoples Hospital of Hechi, Hechi, Guangxi

Affiliated Hospital of Hebei University, Baoding, Hebei

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

Henan Cancer Hospital, Zhengzhou, Henan

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei

Hubei Cancer Hospital, Wuhan, Hubei

Hunan Cancer Hospital, Changsha, Hunan

Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu

Jiangsu Province Hospital, Nanjing, Jiangsu

Jilin Cancer Hospital, Changchun, Jilin

The General Hospital of Shenyang Military, Shenyang, Liaoning

Yidu Central Hospital of Weifang, Weifang, Shandong

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

Affiliated Zhongshan Hospital of Fudan University, Shanghai, Shanghai Municipality

The First Peoples Hospital of Yibin, Yibin, Sichuan

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou, Zhejiang

Zhejiang Cancer Hospital, Hangzhou, Zhejiang